Navigation Links
Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence

AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer. The trial is expected to accrue 711 patients starting mid-2011 with definitive results expected by 2015. The randomized study will evaluate ProstAtak's ability to prevent prostate cancer recurrence. If successful, it could yield the first drug product for newly diagnosed, localized prostate cancer.

Prostate cancer is the second most common cause of death in American men. The American Cancer Society estimates there were approximately 220,000 new prostate cancer diagnoses in 2010. And, although most patients will live at least 5 years after diagnosis, each year over 60,000 men develop recurrence of the cancer and 32,000 die of their disease.

"The SPA and initiation of this pivotal study are aimed at addressing a critical unmet medical need," said Dr. Estuardo Aguilar-Cordova, Founder and CEO of Advantagene. "If successful, ProstAtak would be the first-ever product to vaccinate against the recurrence of a cancer, in this case prostate cancer."

Since no curative therapy currently exists for recurrent prostate cancer, only palliative treatments that compromise quality of life, such as surgical or medical castration, are employed. Once these approaches fail, options include the recently approved immunotherapy Provenge® (Dendreon) or the chemotherapies Zytiga® (Johnson & Johnson) and Jevtana® (Sanofi), which provide modest survival improvements. Advantagene researchers have taken another approach entirely, i.e. preventing prostate cancer death by preventing recurrence. ProstAtak™ is designed as an "off-the-shelf" drug to kill tumor cells and stimulate a vaccine effect against the patient's specific tumor, in essence activating the patient's own immune system to prevent tumor recurrence.

Historically, development of therapies for newly diagnosed prostate cancer has been hindered by the very slow progression of this disease. "Based on our previous data, we were able to design a novel clinical approach that allows efficacy assessment at 24-36 months," stated Dr. Aguilar-Cordova.

Protocol development was co-chaired by Drs. Theodore DeWeese, Chair of Radiation Oncology at Johns Hopkins, and Peter Scardino, Chief of Surgery and Chair of Urology at Memorial Sloan Kettering Cancer Center. "We are delighted to lead this study. I participated in early trials with this product, and am enthusiastic that this randomized trial will definitively evaluate its potential," stated Dr. Scardino. If successful, this could be a major advance for patients and the development of new therapies for prostate cancer.

Contacts for further information:

For more information about ProstAtak™ and Advantagene, please visit the Company's website at

Company Inquiries:

Brian Guzik

Partnering Inquiries:

Jefferson Davis
Extera Partners
617-225-7700 x245

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Advantagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
2. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
3. ShangPharma Announces First Quarter 2011 Results
4. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
5. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
6. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
7. ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
8. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
9. Spherix Announces First Quarter Financial Results
10. Stem Cell Assurance Announces the Filing of Its Form 10 Registration Statement
11. 3SBio Inc. Announces Unaudited First Quarter 2011 Results
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):